89
A common question is asked by most people, Can simple blood test detect cancer ? Classic cancer screening methods require to take tissue sample of suspected parts of human body for biopsy .These tests are painful, invasive, costly and take lots of time to give test results.Now a company claims that their tests only require a simple blood sample.
New method to detect liver cancer,colorectal cancer & breast cancer
Laboratory for Advanced Medicine (LAM), a commercial-stage medical technology company focused on developing innovative technologies for the early diagnosis of cancers, recently announced new data at the American Association for Cancer Research (AACR) Annual Meeting at the Georgia World Congress Center in Atlanta, Georgia.
Success rate of IvyGene Tests to detect cancer
The data demonstrate LAMs proprietary IvyGene Tests possess the ability to detect liver cancer with 95% sensitivity and 97.5% specificity, breast cancer with 89% sensitivity and 96% specificity and colorectal cancer with 93% sensitivity and 100% specificity.
Early cancer detection is a key advantage for successful treatment, said Dr. Shu Li, LAMs Chairman. Classic screening methods are invasive, costly and time-consuming whereas our tests only require a simple blood sample. Behind this simplicity is a complex technology, developed during years of research at LAM. The early detection of cancer is an unmet medical need, and we believe the potential benefits for society can be enormous.
Validation studies
Three blinded validation studies were performed to evaluate individual panels of DNA methylation markers developed for the detection of liver, breast or colorectal cancers.
How it works IvyGene Tests works ?
By quantifying DNA methylation at the target sites, the cancer-specific markers were able to differentiate with high sensitivity and specificity subjects diagnosed with cancer from both healthy donors and subjects with benign diseases.
The results demonstrate the high diagnostic potential of cfDNA methylation markers isolated from blood for the detection of multiple cancers at various stages. In addition, a quantitative analysis of cfDNA methylation signature provides an opportunity for monitoring the disease. The benefits of a sensitive and specific assay to identify and monitor cancer is anticipated to aid disease management and ultimately, improve patient outcomes.
Medical experts on the panel of Emergency Manager magazine think that this is a revolutionary step in the field of cancer detection.It will make the cancer treatment cheaper and less time consuming.Although commercial cost of these test products are not available to quantify the exact benefit in cancer treatment.
About Laboratory for Advanced Medicine
LAM is a commercial-stage medical technology company focused on developing innovative, noninvasive, nontoxic technologies for the early diagnosis and intervention of cancers. The company is dedicated to building and growing world-class technologies from the laboratory to the clinic.
Headquartered in the United States with offices in California, Texas and Indiana, LAM has collaborations with leading scientists, physicians, research institutions and business leaders in the U.S. and China, combining their experiences to provide the most effective and safest diagnostic technologies to patients and their doctors.
..... .... Login with Google and support us
